Todo DSpace

Listar por tema "albuminuria"

Mostrando ítems 1-8 de 8

    • Assessing performance in pre-season wrestling athletes using biomarkers 

      Papassotiriou I., Nifli A.-P. (2018)
      Introduction: Although regular training introduces the desired changes in athletes’ metabolism towards optimal final performance, literature is rarely focusing on the metabolic responses off-competition. Therefore, the aim ...

    • Cadherin and Wnt signaling pathways as key regulators in diabetic nephropathy 

      Tziastoudi M., Tsezou A., Stefanidis I. (2021)
      Aim A recent meta-analysis of genome-wide linkage studies (GWLS) has identified multiple genetic regions suggestive of linkage with DN harboring hundreds of genes. Moving this number of genetic loci forward into biological ...

    • Dietary antioxidant supplements and uric acid in chronic kidney disease: A review 

      Roumeliotis S., Roumeliotis A., Dounousi E., Eleftheriadis T., Liakopoulos V. (2019)
      Increased serum levels of uric acid have been associated with the onset and development of chronic kidney disease (CKD), cardiovascular disease, and mortality, through several molecular pathogenetic mechanisms, such as ...

    • Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease 

      Georgianos P.I., Vaios V., Roumeliotis S., Leivaditis K., Eleftheriadis T., Liakopoulos V. (2022)
      For almost two decades, the management of patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) was based on the optimal glycemic and blood pressure control as well as on the adequate blockade of ...

    • Fabry disease due to D313Y and novel GLA mutations 

      Koulousios K., Stylianou K., Pateinakis P., Zamanakou M., Loules G., Manou E., Kyriklidou P., Katsinas C., Ouzouni A., Kyriazis J., Speletas M., Germenis A.E. (2017)
      Objectives Our aim is to report four novel α-gal A gene (GLA) mutations resulting in Fabry disease (FD) and provide evidence of pathogenicity of the D313Y mutation regarding which contradictory data have been presented in ...

    • Mechanisms for cardiorenal protection of sglt-2 inhibitors 

      Georgianos P.I., Vaios V., Dounousi E., Salmas M., Eleftheriadis T., Liakopoulos V. (2021)
      Despite optimal treatment of diabetic kidney disease (DKD) with adequate blood pressure control and agents blocking the renin-angiotensin-system (RAS), the residual cardiorenal risk of these patients remains substantially ...

    • The Renal Endothelium in Diabetic Nephropathy 

      Eleftheriadis, T.; Antoniadi, G.; Pissas, G.; Liakopoulos, V.; Stefanidis, I. (2013)
      Diabetic nephropathy is the leading cause of end-stage renal disease. Diabetes mellitus is characterized by generalized endothelial dysfunction. However, recent data also emphasizes the role of local renal endothelium ...

    • SGLT-2 inhibitors in diabetic kidney disease: What lies behind their renoprotective properties? 

      Georgianos P.I., Divani M., Eleftheriadis T., Mertens P.R., Liakopoulos V. (2019)
      Background: Despite optimal management of diabetic kidney disease (DKD) with intensive glycemic control and administration of agents blocking the renin-angiotensinaldosterone-system, the residual risk for nephropathy ...